Phio Pharmaceuticals (PHIO) Financials

$1.08

$-0.03 (-2.70%)

As on 04-Sep-2026 16:02EDT

Market cap

$13 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	2.66	4.62	3.64	6.33	0.19	0.19
Gross Profit	-2.66	-4.62	-3.64	-6.33	-0.19	-0.19
Operating Expenses	10.82	4.60	3.74	4.49	11.46	13.51
Operating Profit (EBIT)	-13.47	-9.22	-7.39	-10.82	-11.46	-13.51
Other Income	--	--	--	--	--	--
Profit before Tax	-12.90	-8.70	-7.15	-10.83	-11.48	-13.29
Provision for Tax	--	--	-7.15	0.20	-0.18	-0.08
Profit after Tax (Net Income)	-12.90	-8.70	-7.15	-10.83	-11.31	-13.21
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	--	-13.29

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	12.60	20.15	4.72	7.73	10.84	21.93
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.80	0.91	--	--	0.04	0.17
Current Liabilities	0.90	0.44	1.02	1.63	1.94	3.07
Total Liabilities	15.21	21.49	5.74	9.36	12.81	25.17

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.01	0.01	0.00	0.04	0.37	0.44
Current Assets	14.30	21.48	5.74	9.32	12.45	24.73
Total Assets	16.01	21.49	5.74	9.36	12.81	25.17
Total Debt*	--	--	--	0.04	0.17	0.30
Net Current Assets	12.59	20.14	4.72	7.69	10.51	21.66

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-7.98	-7.11	-10.75	-12.13	-11.86
Cash Flow from Investing Activities	--	-0.01	0.01	-0.01	-0.12	-0.05
Cash from Financing Activities	--	23.64	4.00	7.41	-0.03	21.72
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-1.34	-0.75	-9.08	-26.00	-89.44	-105.53
Cash EPS ($)	-1.29	-0.75	-9.03	-25.55	-87.91	-104.93
Adjusted Book Value ($)	1.09	1.73	6.00	18.56	85.76	175.18
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.69	-9.03	-25.81	-95.96	-94.71
Free Cash Flow per Share ($)	--	-0.69	-9.03	-25.83	-96.91	-95.12

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-69.95	-114.51	-115.32	-68.03	-73.63
ROE (%)	-78.81	-69.95	-114.83	-116.60	-68.99	-75.61
ROA (%)	-90.49	-63.90	-94.69	-97.63	-59.53	-64.59
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	-1.00
EBIT Growth (%)	-142.18	-21.65	33.96	5.55	15.17	-53.66
Net Profit Growth (%)	-82.13	-21.65	33.96	4.24	14.43	-50.24
EPS Growth (%)	69.95	0.92	0.65	0.71	0.15	0.36
Book Value Growth (%)	-48.48	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-1.40	-0.20	-0.03	0.00	-0.01
Price / Book Value	1.00	0.61	0.30	0.04	0.00	0.01
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.61	1.02	0.55	0.76	1.03	1.76
Close Price ($)	1.03	1.05	1.80	6.84	40.18	108.00
High Price ($)	4.19	9.79	10.35	110.43	261.36	470.88
Low Price ($)	0.81	0.97	1.53	6.30	35.10	107.03
Market Cap ($ Cr)	12.55	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	--	--	0.00	0.02	0.01
Short term debt to equity ratio	--	--	--	0.00	0.01	0.01
Current Ratio	15.87	49.37	5.65	5.71	6.42	8.06
Quick Ratio	15.87	--	--	--	--	--
Interest Coverage	-113.19	--	-30.95	--	-65.50	-1,501.22

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	27.21	45.62	41.42	1,004.91	961.63
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.